Lineage Cell Therapeutics, Inc. (LCTX) Financials

LCTX Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 109.5 million 56.8 million
Dec. 31, 2025 112.6 million 69.2 million
Sept. 30, 2025 89.6 million 68.8 million
June 30, 2025 90.8 million 43.7 million

LCTX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -8.1 million 1.2 million
Dec. 31, 2025 -5.0 million 1.1 million
Sept. 30, 2025 -3.6 million 1.2 million
June 30, 2025 -5.6 million 1.2 million

LCTX Net Income

No data available :(

LCTX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 53.4 million - 1.5 million
Dec. 31, 2025 55.8 million - 1.6 million
Sept. 30, 2025 40.5 million - 2.6 million
June 30, 2025 42.3 million - 2.2 million

LCTX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 261.2 million
Dec. 31, 2025 230.1 million
Sept. 30, 2025 228.9 million
June 30, 2025 228.4 million

LCTX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 55000 4.2 million 5.1 million -
Dec. 31, 2025 111000 8.2 million 4.9 million -
Sept. 30, 2025 12000 3.3 million 4.2 million -
June 30, 2025 14000 3.1 million 4.6 million -

LCTX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 1.7 million 188000
Dec. 31, 2025 6.6 million 66000
Sept. 30, 2025 3.7 million 5000
June 30, 2025 2.8 million 39000

LCTX Revenue by Segment
Graph available only for paid members. Upgrade to see it.

LCTX

Price: $1.24

52 week price:
0.65
2.09

Payout Ratio Range:
-644.09%
0.42%

Earnings Per Share: -0.29 USD

Exchange: ASE

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 400600

Market Capitalization: 299.2 million

Links: